BioCryst Broad-Spectrum Antiviral BCX4430 Shows Effective and Well Tolerated in Yellow Fever Preclinical Disease Model
Pharmaceuticals, Inc. (NASDAQ: BCRX) today announced
proof-of-principle data demonstrating that BCX4430 is efficacious and
well tolerated in a preclinical disease model for evaluating efficacy
against yellow fever virus infection. BCX4430 is the lead compound in
BioCryst's broad-spectrum antiviral (BSAV) research program. The
objective of BioCryst's BSAV program is to develop broad-spectrum
parenteral and oral therapeutics for viruses that pose a threat to
national health and security.
A presentation entitled “BCX4430, an adenosine analog, with potent
activity against yellow fever virus in a hamster model,” will be
presented by Dr. Justin Julander at the 2nd Antivirals Congress in
Cambridge, MA today at 5:10PM E.T.